Next-generation immunotherapy: the promise and pitfalls

Join Linda Mathiasson, Strategic Customer Leader for Nucleic Acid Therapeutics at Cytiva, to look at the history of mRNA immunotherapy, cancer vaccine models, and challenges that manufacturers and solution providers must address to achieve this technology’s promise.

Working in next-generation immunotherapy? We're your helping hand for advanced therapies. Learn more about our end-to-end solutions and expertise for developers of next-generation therapies. Visit: https://cytiva.link/pch48